Unipark Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 3 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 420.35%
- Profit Growth 2.31%
- Ebitda 11.80%
- Net Worth -120.30%
- Total Assets 58.02%
About Unipark Biotech
Unipark Biotech Private Limited (UBPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 July 2021 (Three years and seven months 18 days old ). Its registered office is in Jaipur, Rajasthan, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ashish Chhaba, Monika, and Jai Sajnani serve as directors at the Company.
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24239RJ2021PTC075754
- Company No.
075754
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jul 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Unipark Biotech?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashish Chhaba  | Director | 07-Jul-2021 | Current |
| Monika | Director | 07-Jul-2021 | Current |
| Jai Sajnani | Director | 05-Mar-2022 | Current |
Financial Performance of Unipark Biotech.
Unipark Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 420.35% increase. The company also saw a slight improvement in profitability, with a 2.31% increase in profit. The company's net worth observed a substantial decline by a decrease of 120.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unipark Biotech?
Unlock access to Unipark Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Nutrock Nutrition (India) Private LimitedAshish Chhaba is a mutual person
- Nexkem Essentials Private Limited
Ashish Chhaba and Jai Sajnani are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Unipark Biotech?
Unlock and access historical data on people associated with Unipark Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unipark Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unipark Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.